戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 c expansion in a chronic helminth infection (lymphatic filariasis).
2 ndazole, diethylcarbamazine (IDA) regime for Lymphatic Filariasis.
3 d from 67 North Americans with no history of lymphatic filariasis.
4 s into the ecology and pathogenesis of human lymphatic filariasis.
5 mmatory diseases such as river blindness and lymphatic filariasis.
6  evaluation of programs aimed at eliminating lymphatic filariasis.
7 de Brugia malayi, a causative agent of human lymphatic filariasis.
8 cy of IFN-gamma- and IL-4-producing cells in lymphatic filariasis.
9 malayi, one of the causative agents of human lymphatic filariasis.
10 closely associated with cytokine patterns in lymphatic filariasis.
11 upport the elimination of onchocerciasis and lymphatic filariasis.
12 s were visited at 12 months and retested for lymphatic filariasis.
13  is used for the prevention and treatment of lymphatic filariasis.
14 sus macaque serum N-glycans are specific for lymphatic filariasis.
15 histosomiasis, as well as onchocerciasis and lymphatic filariasis.
16 explaining the heterogeneous distribution of lymphatic filariasis.
17 atients, leading to an effective therapy for lymphatic filariasis.
18 Wolbachia drugs that cure onchocerciasis and lymphatic filariasis.
19 and related parasitic nematodes resulting in lymphatic filariasis.
20 sport in Brugia malayi, a causative agent of lymphatic filariasis.
21 s the potential to accelerate elimination of lymphatic filariasis.
22  parasitic diseases like river blindness and lymphatic filariasis.
23 a bancrofti, one of the nematodes that cause lymphatic filariasis.
24  and Mansonia africana, which are vectors of lymphatic filariasis.
25 is virus, as well as of nematodes that cause lymphatic filariasis.
26 hanism underlying T cell immune tolerance in lymphatic filariasis.
27 igen-specific T-cell response seen in patent lymphatic filariasis.
28 ation of the vector-borne parasitic disease, lymphatic filariasis.
29 ssion-stage Brugia malayi, an agent of human lymphatic filariasis.
30 llenge the concept of protective immunity in lymphatic filariasis, 19 adult residents of a Wuchereria
31 n settings with a low baseline prevalence of lymphatic filariasis (5%), the triple-drug regimen reduc
32  based on survey data of schistosomiasis and lymphatic filariasis across four countries.
33 sitic diseases including river blindness and lymphatic filariasis affect hundreds of millions of peop
34    Diethylcarbamazine (DEC) is used to treat lymphatic filariasis and activates TRP-2, GON-2 & CED-11
35  which is associated with disease in chronic lymphatic filariasis and could potentially have an impor
36                                              Lymphatic filariasis and intestinal helminth infections
37                                              Lymphatic filariasis and loiasis are major human disease
38 ases caused by filarial nematodes, including lymphatic filariasis and onchocerciasis (river blindness
39                                              Lymphatic filariasis and onchocerciasis are neglected tr
40                                              Lymphatic filariasis and onchocerciasis are parasitic he
41                                              Lymphatic filariasis and onchocerciasis are parasitic he
42                                              Lymphatic filariasis and onchocerciasis cases responded
43                                     Although lymphatic filariasis and onchocerciasis have been target
44 ach to larger-scale ivermectin treatment for lymphatic filariasis and onchocerciasis in areas where L
45                            Nematodes causing lymphatic filariasis and onchocerciasis rely on their ba
46                 Filarial diseases, including lymphatic filariasis and onchocerciasis, are considered
47 ssential for parasitic worms responsible for lymphatic filariasis and onchocerciasis, devastating hum
48 cy of minocycline treatment regimens against lymphatic filariasis and onchocerciasis.
49 ld be used in the global effort to eliminate lymphatic filariasis and possibly for the control of oth
50  mass drug administration for elimination of lymphatic filariasis and soil-transmitted helminth infec
51 rack to achieve their elimination goals (for lymphatic filariasis and trachoma) by 2020 or 2021 and t
52 parasitic worms such as Brugia, which causes lymphatic filariasis and Trichuris, one of the soil-tran
53 ombination to reduce microfilariae in blood (lymphatic filariasis) and skin (onchocerciasis).
54  animal diseases, including West Nile virus, lymphatic filariasis, and avian malaria, posing a consta
55 motherapeutic agents against onchocerciasis, lymphatic filariasis, and heartworm.
56 eases, such as guinea worm, schistosomiasis, lymphatic filariasis, and onchocerciasis, suggests that
57 tion drives employed against onchocerciasis, lymphatic filariasis, and several other parasitic diseas
58 ydrocoele, lymphoedema, and elephantiasis in lymphatic filariasis, and skin disease and blindness in
59 ty of diseases including West Nile virus and lymphatic filariasis, and transmit pathogens threatening
60 el of the within-host population dynamics of lymphatic filariasis, and use a simulated goodness-of-fi
61 he impaired Th1 responses observed in patent lymphatic filariasis are associated with decreased expre
62                  Global efforts to eliminate lymphatic filariasis are based on the annual mass admini
63 ividual clearance or community prevalence of lymphatic filariasis at 12 months, and no improved effic
64 tration campaigns against onchocerciasis and lymphatic filariasis being conducted in areas where Onch
65 asites responsible for malaria (Plasmodium), lymphatic filariasis (Brugia,Wuchereria bancrofti), giar
66 ss the potential for school-based control of lymphatic filariasis by investigating the efficacy and t
67 a (TPE), a potentially fatal complication of lymphatic filariasis, by mechanisms that are incompletel
68 tration with ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa
69 eived diethylcarbamazine and albendazole for lymphatic filariasis control.
70       However, few such programmes exist for lymphatic filariasis, despite evidence that single-dose
71 provide evidence that protective immunity to lymphatic filariasis does occur and that it is probably
72                 Conventional oral therapy of lymphatic filariasis drugs is only effective to kill mic
73                                              Lymphatic filariasis (elephantiasis) is a global public
74    The low prevalence levels associated with lymphatic filariasis elimination pose a challenge for ef
75 rne diseases, including dengue, malaria, and lymphatic filariasis, exact a devastating toll on global
76                                              Lymphatic filariasis, frequently caused from Wuchereria
77 he potential to assist programs in achieving lymphatic filariasis goals.
78            The Global Programme to Eliminate Lymphatic Filariasis (GPELF) aims to reduce and maintain
79 s and exciting Global Programme to Eliminate Lymphatic Filariasis (GPELF) is largely based on a strat
80            The Global Programme to Eliminate Lymphatic Filariasis (GPELF) provides antifilarial medic
81            The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with t
82            The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with t
83              The Global Program to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with t
84  the Global Programme for the Elimination of Lymphatic Filariasis (GPELF), as interaction dynamics ma
85 o continue the Global Programme to Eliminate Lymphatic Filariasis (GPELF).
86 egy for the elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa
87          Overall, ccfDNA/ccfRNA detection in lymphatic filariasis holds promise for assessment of inf
88 s potential to accelerate the elimination of lymphatic filariasis if high population coverage of mass
89 s potential to accelerate the elimination of lymphatic filariasis if high population coverage of mass
90 and community impact of IDA vs DA as MDA for lymphatic filariasis in 35 villages on 2 islands of Fiji
91 n programs for control of onchocerciasis and lymphatic filariasis in Africa.
92 mens are needed to accelerate elimination of lymphatic filariasis in Africa.
93 s administration of albendazole to eliminate lymphatic filariasis in areas where loiasis is co-endemi
94 drug regimen for accelerating elimination of lymphatic filariasis in different epidemiological settin
95 luated our methodology using a case study of lymphatic filariasis in Ghana, demonstrating that a geos
96  the extracellular parasites responsible for lymphatic filariasis in humans--and the APC with which t
97 om adult Brugia malayi, a causative agent of lymphatic filariasis in humans.
98  disability in the developing world, causing lymphatic filariasis in nearly 40 million people.
99                           Onchocerciasis and lymphatic filariasis in particular are the cause of much
100 parasitic nematode of humans responsible for lymphatic filariasis, in a longitudinal cohort of infect
101 ilia (TPE) is a severe asthmatic syndrome of lymphatic filariasis, in which an allergic response is i
102                                              Lymphatic filariasis is a disease characterized by immun
103   The current global initiative to eliminate lymphatic filariasis is a major renewed commitment to re
104                                              Lymphatic filariasis is a tropical disease caused by the
105                                              Lymphatic filariasis is a vector-borne neglected tropica
106                                       Patent lymphatic filariasis is characterized by a profound down
107                                       Patent lymphatic filariasis is characterized by antigen-specifi
108                                       Patent lymphatic filariasis is characterized by profound Ag-spe
109  population living on a Pacific island where lymphatic filariasis is endemic.
110 gen-specific T-cell unresponsiveness seen in lymphatic filariasis is mediated, in part, by diminished
111 f lymphedema development in individuals with lymphatic filariasis is presently poorly understood.
112  broad spectra of clinical manifestations of lymphatic filariasis is still unknown.
113            Elimination of onchocerciasis and lymphatic filariasis is targeted for 2020.
114                                              Lymphatic filariasis is targeted for elimination as a pu
115                                              Lymphatic filariasis is the major global cause of nonher
116                                              Lymphatic filariasis (LF) afflicts over 60 million peopl
117                                              Lymphatic filariasis (LF) and onchocerciasis are priorit
118                     Available treatments for lymphatic filariasis (LF) are limited in their longterm
119 aunched in 2000 with the goal of eliminating lymphatic filariasis (LF) as a public health problem by
120 pects of achieving the global elimination of lymphatic filariasis (LF) by 2020.
121                                  Malaria and lymphatic filariasis (LF) continue to cause a considerab
122 l is widely considered an important tool for lymphatic filariasis (LF) elimination but is not usually
123 uitoes, is a recommended approach to support lymphatic filariasis (LF) elimination efforts.
124 tration (MDA) programs that aim to eliminate lymphatic filariasis (LF) in Africa.
125 on people are currently at risk of acquiring lymphatic filariasis (LF) in over 52 countries worldwide
126 ended as a possible strategy for eliminating lymphatic filariasis (LF) in post-conflict countries suc
127                                              Lymphatic filariasis (LF) is a debilitating, poverty-pro
128                                              Lymphatic filariasis (LF) is a major cause of acute and
129                    The global elimination of lymphatic filariasis (LF) is a major focus of the World
130                                              Lymphatic filariasis (LF) is a neglected tropical diseas
131                                        Human lymphatic filariasis (LF) is primarily caused by the hel
132              The familial recurrence risk of lymphatic filariasis (LF) is unknown.
133       In the global drive for elimination of lymphatic filariasis (LF), 15 countries have achieved va
134 eases of public health importance, including lymphatic filariasis (LF), as well as many arboviral dis
135 neglected tropical diseases (NTD), including lymphatic filariasis (LF), scaled up dramatically after
136 e global communities tasked with eliminating lymphatic filariasis (LF), the underlying cause of eleph
137                                              lymphatic filariasis (LF).
138 c worms and one of the etiological agents of Lymphatic filariasis (LF).
139 A) is the cornerstone for the elimination of lymphatic filariasis (LF).
140  is the main strategy for the elimination of lymphatic filariasis (LF).
141                These foci are coendemic with lymphatic filariasis (LF).
142 ration (MDA) with albendazole (ALB) alone on lymphatic filariasis (LF).
143                       Using rodent models of lymphatic filariasis (Litomosoides sigmodontis) and nonc
144  Individuals with clinical manifestations of lymphatic filariasis may be currently infected or not.
145                                              Lymphatic filariasis occurs in endemic pockets.
146  programs, the data available for five NTDs (lymphatic filariasis, onchocerciasis, intestinal helmint
147 ng serum samples from patients with loiasis, lymphatic filariasis, onchocerciasis, mansonellosis, or
148 al NTDs, namely gambiense sleeping sickness, lymphatic filariasis, onchocerciasis, schistosomiasis, s
149  for the coadministration of drugs to target lymphatic filariasis, onchocerciasis, schistosomiasis, s
150 soil-transmitted helminths, schistosomiasis, lymphatic filariasis, onchocerciasis, trachoma, visceral
151 Wolbachia from filarial nematodes that cause lymphatic filariasis or onchocerciasis, resulting in blo
152 -transmitted helminthiases, schistosomiasis, lymphatic filariasis) or elimination of transmission (on
153       To test this hypothesis in bancroftian lymphatic filariasis, pedigree data were collected twice
154 , dengue fever and yellow fever viruses, and lymphatic filariasis, respectively.
155 tages of Brugia malayi, a causative agent of lymphatic filariasis, resulting in the identification of
156                                 Focussing on lymphatic filariasis, schistosomiasis and soil-transmitt
157 cific Th1 and Th2 immune responses occurs in lymphatic filariasis that is governed at the transcripti
158 target the elimination and control of 5 NTDs-lymphatic filariasis, trachoma, onchocerciasis, schistos
159 schistosomiasis, soil-transmitted helminths, lymphatic filariasis, trachoma, onchocerciasis, visceral
160  least five rounds of community-wide MDA for lymphatic filariasis, was divided into 40 clusters (popu
161                                        Human lymphatic filariasis, which afflicts an estimated 120 mi
162 as malaria, tuberculosis, leishmaniasis, and lymphatic filariasis, which impose tremendous public hea
163 e is a safe and well-tolerated treatment for lymphatic filariasis with significant activity against a
164 of Brugia malayi, a causative agent of human lymphatic filariasis, with PBMC of normal individuals.
165  doxycycline treatment on the major cause of lymphatic filariasis, Wuchereria bancrofti.

 
Page Top